AACR

10 czerwca 2025

American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025

Rok

2025

Cel

RVU 305 (PRMT5), ONCO Prime, Novel Targets

Postery naukowe

  • plik pdf

    Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment

    Pobierz
  • plik pdf

    Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies

    Pobierz